Business Context and Reporting Period
Company: Editas Medicine, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2015
Business Overview: Editas Medicine is a preclinical-stage biotechnology company developing a proprietary genome editing platform based on CRISPR/Cas9 technology. The company focuses on treating genetically defined diseases, with its most advanced program targeting Leber Congenital Amaurosis type 10 (LCA10), a form of inherited blindness. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Financial Metric (in thousands) | Year Ended Dec 31, 2015 | Year Ended Dec 31, 2014 |
|---|---|---|
| Collaboration Revenue | $1,629 | $0 |
| Total Operating Expenses | $36,941 | $12,723 |
| Net Loss | $(72,900) | $(13,685) |
| Cash and Cash Equivalents | $143,180 | $10,623 |
| Working Capital | $138,060 | $4,555 |
| Accumulated Deficit | $(88,300) | $(15,292) |
Note: The significant increase in cash and working capital in 2015 was driven by private placements of preferred stock ($142 million) and an upfront payment from a collaboration agreement ($25 million). The company completed its Initial Public Offering (IPO) in February 2016, raising approximately $97.8 million in net proceeds, which is not reflected in the December 31, 2015 balance sheet.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $1.6 million in collaboration revenue in 2015, compared to zero in 2014. This revenue stems from a collaboration agreement with Juno Therapeutics entered into in May 2015.
- Operating Expenses: Total operating expenses increased by 190% to $36.9 million in 2015 from $12.7 million in 2014. Research and Development (R&D) expenses rose to $18.8 million (from $5.1 million), and General and Administrative (G&A) expenses rose to $18.1 million (from $7.7 million) due to expanded operations and personnel.
- Net Loss: Net loss increased significantly to $72.9 million in 2015 from $13.7 million in 2014. This increase was primarily driven by higher operating expenses and a $37.4 million non-cash "Other expense, net" related to the re-measurement of liabilities associated with preferred stock tranche rights and anti-dilutive protection.
- Liquidity: Cash and cash equivalents increased from $10.6 million to $143.2 million, reflecting successful capital raising activities.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Profitability: The company expects to continue to incur significant expenses and operating losses for the foreseeable future. It does not expect to be profitable in 2016.
- Capital Needs: Management anticipates that net proceeds from the IPO (closed Feb 2016), existing cash, and anticipated research support from Juno Therapeutics will fund operations for at least the next 24 months following the IPO.
- Development Timeline: The company aims to initiate a clinical trial for its LCA10 program in 2017. All other programs remain in the preclinical or research stage.
Material Risks and Contingencies
- Intellectual Property Disputes: A significant risk involves a declared interference proceeding at the USPTO between the company's in-licensed patents (from Broad Institute/MIT/Harvard) and a pending application owned by the University of California/University of Vienna/Emmanuelle Charpentier. The outcome could materially affect the company's ability to commercialize its technology.
- Regulatory Uncertainty: As a novel genome editing technology, the regulatory pathway for CRISPR/Cas9 products is uncertain. No genome editing products have been approved in the US or EU.
- Dependence on Third Parties: The company relies on third-party manufacturers for preclinical materials and Juno Therapeutics for a significant portion of its current revenue and future potential milestones.
- Off-Target Effects: There is a risk that the genome editing technology could cause unintended genetic changes ("off-target" effects), which could halt clinical development or lead to liability.
Key Facts for Investor Verification
- Patent Interference Status: Verify the current status of the USPTO interference proceeding involving the University of California and Broad Institute/MIT/Harvard, as this directly impacts the validity of the company's core IP.
- Collaboration Milestones: Review the specific terms of the Juno Therapeutics agreement to understand the conditions required to trigger the $22 million in research support and the potential $700 million in milestone payments.
- Cash Burn Rate: Monitor the rate of cash consumption relative to the $143 million cash balance (as of Dec 31, 2015) plus the $97.8 million IPO proceeds to assess the runway before additional financing is required.
- LCA10 Clinical Trial Initiation: Track progress toward the stated goal of initiating a clinical trial for LCA10 in 2017, including the submission of an Investigational New Drug (IND) application.
- License Obligations: Confirm the company's ability to meet diligence and milestone obligations under its license agreements with Broad Institute, Harvard, MIT, MGH, and Duke University to avoid termination of rights.